Specific TNF-alpha inhibition in cerebral aneurysm formation and subarachnoid hemorrhage

Current Drug Safety

Volumn 7, Issue 3, 2012, Pages 190-196

  Young, Adam M H ^a,b   Karri, Surya K ^a   You, Wanchun ^a   Ogilvy, Christopher S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Aneurysm; Inflammation; SAH; TNF

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; BRAIN ARTERY ANEURYSM; BRAIN BLOOD VESSEL; BRAIN VASOSPASM; CYTOKINE PRODUCTION; DNA POLYMORPHISM; EXPERIMENTAL MODEL; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SUBARACHNOID HEMORRHAGE;

ANIMALS; CEREBROVASCULAR CIRCULATION; HUMANS; INTRACRANIAL ANEURYSM; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION; SUBARACHNOID HEMORRHAGE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84870349697     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488612803251315     Document Type: Article

References (79)

1. Macpherson KJ, Lewsey JD, Jhund PS, et al. Trends in incidence and in short term survival following a subarachnoid haemorrhage in Scotland, 1986-2005: a retrospective cohort study. BMC Neurol 2011;11: 38.
2. Aoki H, Takada Y, Kondo S, Sawaya R, Aggarwal BB, Kondo Y. Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol 2007; 72: 29-39.
3. Kapadia SR, Yakoob K, Nader S, Thomas JD, Mann DL, Griffin BP. Elevated circulating levels of serum tumor necrosis factoralpha in patients with hemodynamically significant pressure and volume overload. J Am Coll Cardiol 2000; 36: 208-12.
4. Munoz J, Albillos A, Perez-Paramo M, Rossi I, Alvarez-Mon M. Factors mediating the hemodynamic effects of tumor necrosis factor-alpha in portal hypertensive rats. Am J Physiol 1999; 276: G687-93.
5. Giraldo EA, Mandrekar JN, Rubin MN, et al. Timing of clinical grade assessment and poor outcome in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 2012; 117: 15-9.
6. Rosendahl MS, Ko SC, Long DL, et al. Identification and characterization of a pro-tumor necrosis factor-alpha-processing enzyme from the ADAM family of zinc metalloproteases. J Biol Chem 1997; 272: 24588-93.
7. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729-33.
8. Wang J, Al-Lamki RS, Zhang H, et al. Histamine antagonizes tumor necrosis factor (TNF) signaling by stimulating TNF receptor shedding from the cell surface and Golgi storage pool. J Biol Chem 2003; 278: 21751-60.
9. Robak T, Gladalska A, Stepien H. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. Eur Cytokine Netw 1998; 9: 145-54.
10. Nurnberger W, Platonov A, Stannigel H, et al. Definition of a new score for severity of generalized Neisseria meningitidis infection. Eur J Pediatr 1995; 154: 896-900.
11. Al-Lamki RS, Wang J, Skepper JN, Thiru S, Pober JS, Bradley JR. Expression of tumor necrosis factor receptors in normal kidney and rejecting renal transplants. Lab Invest 2001; 81: 1503-15.
12. Jones SJ, Ledgerwood EC, Prins JB, et al. TNF recruits TRADD to the plasma membrane but not the trans-Golgi network, the principal subcellular location of TNF-R1. J Immunol 1999; 162: 1042-8.
13. Bennett M, Macdonald K, Chan SW, Luzio JP, Simari R, Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 1998; 282: 290-3.
14. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000; 288: 2351-4.
15. Jiang Y, Woronicz JD, Liu W, Goeddel DV. Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. Science 1999; 283: 543-6.
16. Endres R, Hacker G, Brosch I, Pfeffer K. Apparently normal tumor necrosis factor receptor 1 signaling in the absence of the silencer of death domains. Mol Cell Biol 2003; 23: 6609-17.
17. Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV. TNFdependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 1996; 4: 387-96.
18. Takeuchi M, Rothe M, Goeddel DV. Anatomy of TRAF2. Distinct domains for nuclear factor-kappaB activation and association with tumor necrosis factor signaling proteins. J Biol Chem 1996; 271: 19935-42.
19. Bradley JR, Johnson DR, Pober JS. Four different classes of inhibitors of receptor-mediated endocytosis decrease tumor necrosis factor-induced gene expression in human endothelial cells. J Immunol 1993; 150: 5544-55.
20. Schutze S, Machleidt T, Adam D, et al. Inhibition of receptor internalization by monodansylcadaverine selectively blocks p55 tumor necrosis factor receptor death domain signaling. J Biol Chem 1999; 274: 10203-12.
21. Yang J, Lin Y, Guo Z, et al. The essential role of MEKK3 in TNFinduced NF-kappaB activation. Nat Immunol 2001; 2: 620-4.
22. Blonska M, Shambharkar PB, Kobayashi M, et al. TAK1 is recruited to the tumor necrosis factor-alpha (TNF-alpha) receptor 1 complex in a receptor-interacting protein (RIP)-dependent manner and cooperates with MEKK3 leading to NF-kappaB activation. J Biol Chem 2005; 280: 43056-63.
23. Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 2005; 7: 758-65.
24. Nishitoh H, Saitoh M, Mochida Y, et al. ASK1 is essential for JNK/SAPK activation by TRAF2. Mol Cell 1998; 2: 389-95.
25. Ichijo H, Nishida E, Irie K, et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997; 275: 90-4.
26. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NFkappaB signals induce the expression of c-FLIP. Mol Cell Biol 2001; 21: 5299-305.
27. Xu XS, Vanderziel C, Bennett CF, Monia BP. A role for c-Raf kinase and Ha-Ras in cytokine-mediated induction of cell adhesion molecules. J Biol Chem 1998; 273: 33230-8.
28. Jacinto E, Facchinetti V, Liu D, et al. SIN1/MIP1 maintains rictormTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006; 127: 125-37.
29. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997; 9: 180-6.
30. Jayaraman T, Paget A, Shin YS, et al. TNF-alpha-mediated inflammation in cerebral aneurysms: a potential link to growth and rupture. Vasc Health Risk Manag 2008; 4: 805-17.
31. Gonzalez CF, Cho YI, Ortega HV, Moret J. Intracranial aneurysms: flow analysis of their origin and progression. AJNR Am J Neuroradiol 1992; 13: 181-8.
32. Muñoz J, Albillos A, Pérez-Páramo M, Rossi I, Alvarez-Mon M. Factors mediating the hemodynamic effects of tumor necrosis factor-alpha in portal hypertensive rats. Am J Physiol. 1999; 276: G687-93.
33. Paolisso G, Rizzo MR, Mazziotti G, et al. Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha. Am J Physiol 1998; 275: E294-9.
34. Kirwan JP, Krishnan RK, Weaver JA, Del Aguila LF, Evans WJ. Human aging is associated with altered TNF-alpha production during hyperglycemia and hyperinsulinemia. Am J Physiol Endocrinol Metab 2001; 281: E1137-43.
35. Anto RJ, Mukhopadhyay A, Shishodia S, Gairola CG, Aggarwal BB. Cigarette smoke condensate activates nuclear transcription factor-kappaB through phosphorylation and degradation of IkappaB(alpha): correlation with induction of cyclooxygenase-2. Carcinogenesis 2002; 23: 1511-8.
36. Sun SH, Tang WX, Liu C, Lin H, Yang HH. Effects of tumor necrosis factor alpha on proteolysis of respiratory muscles in rats with chronic obstructive pulmonary disease. Zhonghua Jie He He Hu Xi Za Zhi 2007; 30: 186-91.
37. Lanzke N, Kleinwachter R, Kerschischnik S, et al. Differential effects of ethanol on IFN-gamma-and TNF-alpha-producing splenic T lymphocytes in a murine model of gram-negative pneumonia. Addict Biol 2007; 12: 59-68.
38. Chyatte D, Bruno G, Desai S, Todor DR. Inflammation and intracranial aneurysms. Neurosurgery. 1999; 45: 1137-46.
39. Hanafy KA, Grobelny B, Fernandez L, et al. Brain interstitial fluid TNF-alpha after subarachnoid hemorrhage. J Neurol Sci 2010; 291: 69-73.
40. Tracey KJ, Cerami A. Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol 1993; 9: 317-43.
41. Messadi DV, Pober JS, Fiers W, Gimbrone MA Jr, Murphy GF. Induction of an activation antigen on postcapillary venular endothelium in human skin organ culture. J Immunol 1987; 139: 1557-62.
42. Bradley JR, Pober JS. Prolonged cytokine exposure causes a dynamic redistribution of endothelial cell adhesion molecules to intercellular junctions. Lab Invest 1996; 75: 463-72.
43. Vestweber D. Molecular mechanisms that control leukocyte extravasation through endothelial cell contacts. Ernst Schering Found Symp Proc 2007; 151-67.
44. Pober JS. Effects of tumour necrosis factor and related cytokines on vascular endothelial cells. Ciba Found Symp 1987; 131: 170-84.
45. Munro JM, Pober JS, Cotran RS. Tumor necrosis factor and interferon-gamma induce distinct patterns of endothelial activation and associated leukocyte accumulation in skin of Papio anubis. Am J Pathol 1989; 135: 121-33.
46. Rollins BJ, Yoshimura T, Leonard EJ, Pober JS. Cytokineactivated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. Am J Pathol 1990; 136: 1229-33.
47. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986; 83: 4533-7.
48. Fontanella M, Rainero I, Gallone S, et al. Tumor necrosis factoralpha gene and cerebral aneurysms. Neurosurgery 2007; 60: 668-72.
49. Beeftink MM, Ruigrok YM, Rinkel GJ, van den Bergh WM. Relation of serum TNF-β and TNF-β genotype with delayed cerebral ischemia and outcome in subarachnoid hemorrhage. Neurocrit Care 2011; 15: 405-9.
50. Maddahi A, Kruse LS, Chen QW, Edvinsson L. The role of tumor necrosis factor-β and TNF-β receptors in cerebral arteries following cerebral ischemia in rat. J Neuroinflamm. 2011; 8: 107.
51. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907-16.
52. Atzeni F, Sarzi-Puttini P, Botsios C, et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 2012 Jul 13; [Epub ahead of print].
53. Lopez-Sanroman A, Gisbert JP. Letter: infliximab and adalimumab in the management of Crohn's disease-are they really comparable? Aliment Pharmacol Ther 2012; 36: 498-9.
54. Chalouhi N, Ali MS, Jabbour PM, Tjoumakaris SI, et al. Biology of intracranial aneurysms: role of inflammation. J Cereb Blood Flow Metab. 2012 Jul 11. doi: 10.1038/jcbfm.2012.84. [Epub ahead of print]
55. Hurlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factoralpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106: 2184-7.
56. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 83-6.
57. Komai N, Morita Y, Sakuta T, Kuwabara A, Kashihara N. Antitumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod Rheumatol 2007; 17: 385-90.
58. Gonzalez-Juanatey C, Llorca J, Sanchez-Andrade A, Garcia-Porrua C, Martin J, Gonzalez-Gay MA. Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol 2006; 24: 309-12.
59. Bosello S, Santoliquido A, Zoli A, et al. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin Rheumatol 2008; 27: 833-9.
60. Sidiropoulos PI, Siakka P, Pagonidis K, et al. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. Scand J Rheumatol 2009; 38: 6-10.
61. Maltete D, Bellien J, Cabrejo L, et al. Hypertrophic remodeling and increased arterial stiffness in patients with intracranial aneurysms. Atherosclerosis 2010; 211: 486-91.
62. Del Porto F, Lagana B, Lai S, et al. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 1111-5.
63. Wong M, Oakley SP, Young L, et al. Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1277-84.
64. Maki-Petaja KM, Hall FC, Booth AD, et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006; 114: 1185-92.
65. Parkhutik V, Lago A, Tembl JI, Beltrán A, Fuset MP. Spontaneous subarachnoid haemorrhage: a study of 462 patients. Rev Neurol 2008; 46: 705-8.
66. Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005; 64: 765-6.
67. Soubrier M, Jouanel P, Mathieu S, et al. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine 2008; 75: 22-4.
68. Garces SP, Parreira Santos MJ, Vinagre FM, Roque RM, da Silva JAC. Anti-tumour necrosis factor agents and lipid profile: a class effect? Ann Rheum Dis 2008; 67: 895-6.
69. Migita K, Maeda Y, Miyashita T, et al. The serum levels of resistin in rheumatoid arthritis patients. Clin Exp Rheumatol 2006; 24: 698-701.
70. Lewicki M, Kotyla P, Kucharz E. Etanercept increases adiponectin level in woman with rheumatoid arthritis. Clin Rheumatol 2008; 27: 1337-8.
71. Rosenvinge A, Krogh-Madsen R, Baslund B, Pedersen BK. Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. Scand J Rheumatol 2007; 36: 91-6.
72. van Eijk IC, de Vries MK, Levels JH, et al. Improvement of lipid profile is accompanied by atheroprotective alterations in highdensity lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum 2009; 60: 1324-30.
73. Van Doornum S, McColl G, Wicks IP. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 1428-32.
74. Nishida K, Okada Y, Nawata M, Saito K, Tanaka Y. Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody. Endocr J 2008; 55: 213-6.
75. Spanakis E, Sidiropoulos P, Papadakis J, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006; 33: 2440-6.
76. Saiki O, Takao R, Naruse Y, Kuhara M, Imai S, Uda H. Infliximab but not methotrexate induces extra-high levels of VLDLtriglyceride in patients with rheumatoid arthritis. J Rheumatol 2007; 34: 1997-2004.
77. Tam LS, Tomlinson B, Chu TT, Li TK, Li EK. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 2007; 26: 1495-8.
78. Oguz FM, Oguz A, Uzunlulu M. The effect of infliximab treatment on insulin resistance in patients with rheumatoid arthritis. Acta Clin Belg 2007; 62: 218-22.
79. Kerekes G, Soltész P, Szucs G, et al. Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis. Isr Med Assoc J. 2011; 13: 147-52.